Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Cardiff Oncology Inc. sell shadow

Start price
€9.90
22.09.20 / 50%
Target price
-
04.11.21
Performance (%)
-49.70%
End price
€4.98
05.11.21
Summary
This prediction ended on 05.11.21 with a price of €4.98. shadow correctly predicted massive losses of -49.70% for Cardiff Oncology Inc.. shadow has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y 3y
Cardiff Oncology Inc. 14.725% 14.725% 283.260% -38.225%
iShares Core DAX® 2.149% 5.415% 21.385% 22.595%
iShares Nasdaq 100 0.838% 1.926% 44.386% 55.330%
iShares Nikkei 225® 1.143% 2.887% 27.641% 9.481%
iShares S&P 500 1.265% 3.698% 33.327% 49.646%

According to shadow what are the pros and cons of Cardiff Oncology Inc. for the foreseeable future?

Pros
Valuable balance sheet
Capable Management
Good culture
Small cyclical dependencies
Cons
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
High valuation
Low dividend yield expected
negative Cash Flow expected
Little Investments for future growth
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Little innovation
Few uniques
Dependend from some customers or products
Growths slower than the competition
Sustainability is little important
Higher risks for its business
Below average Marketposition
Business model of the past or high risk
Little known brand

Comments by shadow for this prediction

In the thread Trovagene diskutieren

Sell Cardiff Oncology Inc.

In the thread Trading Trovagene
Prediction Sell
Perf. (%) -49.70%
Target price
Change
Ends at 04.11.21

Die von shadow gewählte maximale Laufzeit wurde überschritten